The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo

A phase 2 clinical trial investigating the efficacy and safety of AS602801, a newly developed JNK inhibitor, in the treatment of inflammatory endometriosis is complete. We are now examining whether AS602801 acts against human cancer cells in vitro and in vivo. In vitro, AS602801 exhibited cytotoxici...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Okada, Masashi, Kuramoto, Kenta, Takeda, Hiroyuki, Watarai, Hikaru, Sakaki, Hirotsugu, Seino, Shizuka, Seino, Manabu, Suzuki, Shuhei, Kitanaka, Chifumi
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5053629/
https://ncbi.nlm.nih.gov/pubmed/27027242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8395
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky